In an analysis of 43 matched pairs of pre- and post-treatment GBM samples, Felsberg et al., saw significant reductions in expression of MSH2, MSH6, and PMS2, but not MLH1 [39]. This evidence concerns the gene PMS2 and glioblastoma.